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Background: During the 2017/18 and 2018/19 influ-
enza seasons, molecular amplification-based point-
of-care tests (mPOCT) were introduced in Scotland to 
aid triaging respiratory patients for hospital admis-
sion, yet communication of results to national surveil-
lance was unaccounted for. Aim: This retrospective 
study aims to describe steps taken to capture mPOCT 
data and assess impact on influenza surveillance. 
Methods: Questionnaires determined mPOCT usage 
in 2017/18 and 2018/19. Searches of the Electronic 
Communication of Surveillance in Scotland (ECOSS) 
database were performed and compared with infor-
mation stored in laboratory information management 
systems. Effect of incomplete data on surveillance was 
determined by comparing routine against enhanced 
data and assessing changes in influenza activity levels 
determined by the moving epidemic method. Results: 
The number of areas employing mPOCT increased over 
the two seasons (6/14 in 2017/18 and 8/14 in 2018/19). 
Analysis of a small number of areas (n = 3) showed 
capture of positive mPOCT results in ECOSS improved 
between seasons and remained high (> 94%). However, 
capture of negative results was incomplete. Despite 
small discrepancies in weekly activity assessments, 
routine data were able to identify trend, start, peak 
and end of both influenza seasons. Conclusion: This 
study has shown an improvement in capture of data 
from influenza mPOCT and has highlighted issues that 
need to be addressed for results to be accurately cap-
tured in national surveillance. With the clear benefit 
to patient management we suggest careful consider-
ation should be given to the connectivity aspects of 
the technology in order to ensure minimal impact on 
national surveillance.
Introduction
Point-of-care tests (POCT) for influenza have been 
available since the late 1990s [1]. However, these were 
relatively insensitive tests relying on the detection 
of viral antigens. More recently, POCT using molecu-
lar nucleic acid amplification (mPOCT), which have 
increased sensitivity and are comparable to the gold 
standard laboratory PCR tests (hereafter named as 
laboratory-derived tests/results), have become avail-
able making them an attractive and acceptable option 
for frontline healthcare services. mPOCT have been 
implemented and validated within hospital settings 
[2-8], and community settings [9]. A study performed in 
2019 reported that the use of mPOCT in an emergency 
department in London was associated with reduced 
nosocomial transmission of influenza [3]. Another study 
from the Netherlands documented a positive experi-
ence with mPOCT in one teaching hospital, reporting 
reduced turnaround times, improved patient flow and 
estimated savings of roughly EUR 400,000 [4].
Influenza surveillance is an important public health 
activity for ensuring that there are adequate health 
service resources available and appropriate inter-
ventions accessible, particularly for those who are at 
risk of complications of influenza [10,11]. In Scotland, 
influenza activity is monitored on a weekly basis dur-
ing the winter period through a wide range of surveil-
lance components. The national influenza surveillance 
is composed of laboratory results from diagnostic and 
reference laboratories. These are transferred electroni-
cally from individual laboratory information manage-
ment systems (LIMS) to the Electronic Communication 
of Surveillance in Scotland (ECOSS) database, man-
aged by Health Protection Scotland (HPS).
During the 2017/18 influenza season, there were 
moderate to high levels of influenza activity reported 
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across Scotland, putting significant pressure on bed 
occupancy in an already stretched hospital system 
(data not shown). mPOCT were rapidly introduced in 
many of the 14 territorial health boards in Scotland as 
a means of triaging for hospital admission. The intro-
duction of mPOCT was to supplement and not replace 
routine testing and therefore resulted in an increase in 
the total number of patients tested. This had a positive 
effect on local bed occupancy, treatment and infection 
control interventions [12]. However, due to the speed of 
introduction, provision had not necessarily been made 
to enable capture of the results to ECOSS, and the 
impact on national influenza surveillance in Scotland 
was potentially compromised. Prior to the start of the 
2018/19 season, HPS attempted to assess and find 
ways to mitigate the loss of national data as experi-
enced in the previous season. This retrospective study 
aims to describe the steps taken to capture mPOCT 
data, assess the impact on influenza surveillance and 
describe the potential public health challenges result-
ing from the mPOCT roll-out.
Methods
Setting and study population
Scotland is divided into fourteen territorial health 
boards (hereafter referred to as areas A-N), which 
collectively provide healthcare for ca 5.4 million 
inhabitants. Healthcare can be given at a number 
of institutions from general practices, community 
pharmacies, out-of-hours clinics and medical receiv-
ing hospitals. Any of these services could potentially 
offer mPOCT for influenza, but the services that used 
this technology in the 2017/18 and 2018/19 influenza 
seasons were acute hospital-based. The population 
studied was therefore the total number of patients 
that presented with influenza-like illness to an acute 
hospital-based service, were tested for influenza using 
mPOCT and had the results transferred to LIMS.
mPOCT implementation questionnaire
At the end of the 2017/18 influenza season, a question-
naire was developed (Supplement 1) and sent to areas 
A-N to determine the scale of mPOCT implementation. 
This was followed by a teleconference with all respond-
ents that reported the use of mPOCT for influenza. 
Information requested in the questionnaire included 
the test manufacturer, location of the testing unit, who 
carried out the tests, how quality assessment was per-
formed, what testing protocols were followed and how 
the results were reported. This led to the development 
of a nationally agreed advisory statement in November 
2018 on the preferred way to implement mPOCT [12]. 
In 2018/19, a similar questionnaire (Supplement 2) was 
distributed to areas A-N before the beginning of the 
influenza season, but more emphasis was placed on 
the transfer of mPOCT results to LIMS, whether man-
ual entry of results was required and what codes were 
assigned to ensure identification of mPOCT.
Analysis of data transfer from LIMS to ECOSS
Influenza laboratory results available in ECOSS were 
analysed and text fields searched to identify keywords 
or codes that would indicate that the influenza test was 
performed using mPOCT (as reported in the mPOCT 
implementation questionnaire). ECOSS records were 
then categorised as mPOCT positive or mPOCT nega-
tive results and aggregated to obtain weekly counts for 
each laboratory. Data were aggregated from week 40 
2017 to week 20 2018 (season 2017/18) and from week 
40 2018 to week 20 2019 (season 2018/19).
Completeness of mPOCT data in ECOSS
Extracts of the equivalent LIMS mPOCT data for the 
above periods were requested from a small number of 
participating areas (n = 3) to assess the completeness 
of both positive and negative ECOSS mPOCT results. 
Completeness was calculated as:
Table 1
Completeness of positive and negative influenza mPOCT results transferred from LIMS to ECOSS, Scotland, influenza 
seasons 2017/18 and 2018/19
mPOCT result Area











D 164 185 88.6 227 242 93.8 5.2
F 539 838 64.3 559 578 96.7 32.4
M NA NA NA 202 199 > 100 –
Negativec
D NA NA NA NA NA NA –
F 86 1,172 7.3 53 1,333 4.0 −3.4
M NA NA NA NA NA NA –
DIFF: difference; ECOSS: Electronic Communication of Surveillance in Scotland database; LIMS: laboratory information management system; 
mPOCT: molecular amplification-based point-of-care tests; NA: not available.
a Results were obtained from tests carried out from week 40 2017 to week 20 2018 (influenza season 2017/18) and from week 40 2018 to week 
20 2019 (influenza season 2018/19).
b Completeness of data transferred from individual LIMS to the ECOSS database. Completeness calculated as number of ECOSS mPOCT results 
(positive or negative) / number of LIMS mPOCT results (positive or negative).
c Negative results were generally not transferred to ECOSS. They were available for area F due to the laboratory in this area having pre-existing 
data transfer in place for all influenza test results.
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number of ECOSS mPOCT results (positive or nega-
tive)  /  number of LIMS mPOCT results (positive or 
negative).
Impact of mPOCT on microbiological 
surveillance data
For each participating area, the impact of incomplete 
or lacking mPOCT data in the Scottish influenza sur-
veillance was assessed by comparing ECOSS routine 
data (nationally agreed data electronically transferred 
from the local laboratory (LIMS), which may or may not 
include all mPOCT local laboratory-derived results) to 
ECOSS enhanced data (ECOSS data with mPOCT results 
identified through text searches were removed and 
replaced by the LIMS extracted mPOCT data to avoid 
double counting). In order to compare these data, we 
calculated two indicators: (i) proportion of positives 
(number of positive results divided by the number of 
tests performed) and (ii) rate of positives (number of 
positive results expressed per 100,000 population).
Proportion of mPOCT vs laboratory-derived 
positive results and tests
We estimated mPOCT usage between the two seasons 
as a proportion of all positive test results i.e. labora-
tory-derived plus mPOCT (ECOSS enhanced data). For 
this calculation we divided the mPOCT figure provided 
by LIMS by the figure provided by ECOSS enhanced 
data.
Statistical analysis
For each indicator value we calculated the Pearson cor-
relation coefficient (r-value) and compared the respec-
tive influenza activity levels to investigate whether 
having complete mPOCT data would change our inter-
pretation of influenza weekly activity. Weekly influenza 
activity level was defined using the moving epidemic 
method (MEM) [13]. MEM is a standardised method for 
reporting influenza activity adopted by the European 
Centre for Disease Prevention and Control that allows 
intra- and inter-country comparisons. We used MEM to 
calculate intensity thresholds and identify influenza 
activity levels based on the two indicators mentioned 
above (proportion of positives and rate of positives). 
The MEM thresholds were calculated using the ‘mem’ 
R package (R software version 3.5.1 (R Foundation, 
Vienna, Austria), and the package ‘mem’ version 2.14) 
using the predefined configuration, i.e. fixed criterium 
method and a slope parameter of 2.8. For each indicator, 
and based on historical data since the 2010/11 season, 
MEM defined the following weekly influenza activity 
levels [14]: baseline (data below epidemic threshold); 
low (data between epidemic and low thresholds); mod-
erate (data between low and medium thresholds); high 
(data between medium and high thresholds); extraor-
dinary (data above high threshold).
Ethical statement
This study used only aggregate and non-identifiable 
data, therefore no ethical approval was necessary.
Figure 1
Comparison of rate of positive influenza tests per 100,000 population between the ECOSS routine data and ECOSS 
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ECOSS: Electronic Communication of Surveillance in Scotland database; MEM: moving epidemic method.
Results were obtained from tests carried out from week 40 2017 to week 20 2018 (influenza season 2017/18) and from week 40 2018 to week 
20 2019 (influenza season 2018/19).




During the 2017/18 influenza season, six of 14 areas 
reported use of influenza mPOCT compared with eight 
of 14 in the 2018/19 season (Supplement 3). The major-
ity of mPOCT were used at acute hospital admissions 
or emergency departments during the 2017/18 season, 
with more specialised departments (e.g. oncology and 
paediatric ICU) using mPOCT during the 2018/19 sea-
son. With the exception of outlying hospitals where 
testing was performed by laboratory staff, the majority 
of mPOCT were performed by ward staff.
According to additional comments received in the 
questionnaires, training in the first instance was usu-
ally performed by the mPOCT manufacturers, with 
some departments supplementing this with training by 
laboratory staff. Quality assessment was minimal due 
to time and cost restraints, which led to shorter verifi-
cation processes and general acceptance of the manu-
facturer’s sensitivity and specificity claims. All areas 
agreed a local protocol with clinicians as to who should 
be tested and under what circumstances. It was noted 
that during the 2017/18 season this was not always 
adhered to and an increase in number of tests was 
reported due to testing of asymptomatic individuals, 
contacts or members of staff. In all cases, patient man-
agement decisions were based entirely on the result 
of the mPOCT, including use of personal protective 
equipment (PPE), antiviral treatment, admission and 
transfer.
In the 2017/18 influenza season, none of the areas had 
direct transfer of test results from the mPOCT machine 
to their LIMS, thus data transfer was performed man-
ually (frequency variable). In the 2018/19 influenza 
season, despite differences between areas, manual 
entry of mPOCT results was required at some stage 
of the data transfer process. Of note, two areas used 
a central computational system (middleware), which 
received data from multiple mPOCT machines before 
transferring to LIMS. However, this link did not work 
and manual data extraction from the middleware was 
required. In addition, information received from the 
2018/19 questionnaire showed there was no consistent 
use of identifiable mPOCT codes across areas.
Analysis of data transfer from LIMS to 
national database
The analysis of ECOSS data only identified a small num-
ber of areas that had records categorised as mPOCT 
based on text searches (two of six in 2017/18: areas D 
and F; and three of eight in 2018/19: areas D, F and M). 
Due to this, only these areas were further analysed and 
investigated for completeness. The weekly aggregated 
counts for the 2017/18 and 2018/19 seasons were then 
requested from these areas. Among areas D, F and 
M, only area F had negative results available through 
ECOSS, but this was due to the laboratory in this area 
Figure 2
Comparison of proportion of positivea influenza tests between the ECOSS routine data and ECOSS enhanced data collection 
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ECOSS: Electronic Communication of Surveillance in Scotland database; MEM: moving epidemic method.
a Proportion of positives calculated as number of positive tests / number of total tests.
Results were obtained from tests carried out from week 40 2017 to week 20 2018 (influenza season 2017/18) and from week 40 2018 to week 
20 2019 (influenza season 2018/19).
Pearson correlation coefficient between ECOSS routine and ECOSS enhanced data was (A) (r = 0.996) and (B) (r = 0.998).
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having pre-existing data transfer in place for all influ-
enza test results.
Completeness of mPOCT data in ECOSS
The results presented in  Table 1  show the proportion 
of mPOCT positive results captured by ECOSS i.e. com-
pleteness increased between the 2017/18 and 2018/19 
seasons for areas D and F by 5.2% and 32.4%, respec-
tively. In the 2018/19 season, a very high proportion of 
mPOCT positive results was captured by ECOSS (93.8%, 
96.7% and > 100% for areas D, F and M, respectively). 
The proportion of mPOCT negative results captured by 
ECOSS for area F was very low in both seasons (7.3% 
and 4% in 2017/18 and 2018/19, respectively). It was 
not possible to calculate the completeness of mPOCT 
negative results in ECOSS for areas D and M as influ-
enza negative results from laboratories in these areas 
were not routinely captured by ECOSS. Discrepancies 
in mPOCT results between ECOSS and LIMS, as seen in 
area M, were determined to be a result of differences 
in coding, subsequent incorrect data entry into text 
fields, and the code not being recognised by the soft-
ware during data extraction.
Impact of mPOCT on influenza surveillance 
data
Data obtained from area F were used to assess the 
impact of mPOCT in influenza surveillance as it ena-
bled the analysis of both positivity rate and proportion 
of positives (required negative results). In terms of rate 
of positives, the weekly influenza activity level based 
on ECOSS enhanced data was similar to that of ECOSS 
routine data (Figure 1). Both seasons’ data showed a 
very high correlation coefficient (0.996 and 0.999 in 
season 2017/18 and 2018/19, respectively). This is in 
line with the high proportion of positives being cap-
tured by ECOSS in both seasons (Table 1). The low pro-
portion of mPOCT negatives being captured by ECOSS 
meant an overestimation of the proportion of positives 
calculated during the two seasons (Figure 2), i.e. the 
ECOSS routine data showed an artificially higher pro-
portion of positives than the ECOSS enhanced data. 
However, the overall trends remained similar and influ-
enza activity level interpretation was similar for both 
ECOSS datasets for most weeks. There was one week 
in the 2017/18 season (Figure 2A) where level interpre-
tation would have been moderate instead of low if we 
were using ECOSS enhanced data (week 5 2018). In the 
2018/19 season, if we were using the ECOSS enhanced 
data there would have been 3 weeks where activity 
level would have been low instead of moderate (weeks 
1,3, and 8 in 2019) and one week where activity level 
would have been baseline instead of low (week 11 2019) 
(Figure 2B). Despite these sporadic discrepancies, the 
data available in ECOSS for area F allowed the identi-
fication of the start, peak and end of both influenza 
seasons. The intensity of the peak and the timing of the 
start and end of the seasons were the same regardless 
of using ECOSS routine or ECOSS enhanced data.
Proportion of mPOCT vs laboratory-derived 
positive results and tests
There was an increase in the proportion of mPOCT 
among all tests performed (laboratory-derived and 
mPOCT together) in area F from 15.5% to 17.7% in the 
2017/18 and 2018/19 season, respectively (Table 2). 
In addition, the proportion of mPOCT positive results 
among all positive results increased from 34% (2017/18 
season) to 48% (2018/19 season). An increase in the 
proportion of mPOCT positive results among all posi-
tive results was also seen in area D (19% to 42% in 
the 2017/18 and 2018/19 season, respectively), and in 
the 2018/19 season the proportion of mPOCT positive 
results for area M was 45.2% (Table 2).
Discussion
The 2017/18 influenza season was dominated by influ-
enza A(H3N2) which is more likely to affect the elderly 
Table 2
Proportion of influenza mPOCT among all influenza testsa performed in area F by influenza season, and proportion of 
positive influenza mPOCT among all positive influenza testsa for areas F, M and D by season, Scotland, influenza seasons 
2017/18 and 2018/19
Tests Area































All tests F 625 2,010 11,571 12,956 15.5 612 1,911 9,511 10,810 17.7
Positive 
tests
F 539 838 2,166 2,465 34.0 559 578 1,191 1,210 47.8
M NA NA NA NA NA 202 199 443 440 45.2
D 164 185 939 960 19.3 227 242 567 582 41.6
ECOSS: Electronic Communication of Surveillance in Scotland database; LIMS: laboratory information management system; mPOCT: molecular 
amplification-based point-of-care tests; NA: not available.
a Laboratory-derived + mPOCT.
b (ECOSS routine − ECOSS mPOCT) + LIMS mPOCT.
c LIMS mPOCT tests divided by ECOSS enhanced tests.
Results were obtained from tests carried out from week 40 2017 to week 20 2018 (influenza season 2017/18) and from week 40 2018 to week 
20 2019 (influenza season 2018/19).
Proportion of mPOCT tests are a potential proportion due to not all LIMS mPOCT results being reported to ECOSS.
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population [15], but with a noticeable tail of Influenza 
B cases which affects both the young and the elderly 
[16]. mPOCTs were rapidly introduced by health boards 
across Scotland and this study reports the conse-
quential difficulties of this technology for the national 
microbiological surveillance of influenza.
Although different mPOCT systems were used in the 
different areas, the principal technology is the same 
and therefore does not affect the results. Most hos-
pitals wanted to link the mPOCT machines directly to 
their LIMS. However this is technically difficult, requires 
time and local IT support, and is often expensive as 
LIMS providers charge for changes to their systems. 
Inevitably, in almost all cases an mPOCT machine to 
LIMS link was not established. Following the 2017/18 
season, areas were encouraged to include a code in 
their mPOCT results and report this to HPS in order 
to enable differentiation between mPOCT generated 
results from laboratory results. However, this failed to 
be achieved in the 2018/19 season, possibly be due 
to the speed at which mPOCT were implemented, and 
compatibility issues between the different systems 
used.
Data from a small number of areas suggest that in most 
instances the positive cases of influenza are being cap-
tured by the national database (ECOSS). This is in con-
trast with the negative results where there is a sizeable 
gap between local and national figures. Incomplete 
mPOCT negative results data in the national surveil-
lance system will overestimate the proportion of posi-
tives and potentially overestimate the weekly influenza 
activity levels. Despite this, data for area F showed 
that the differences in weekly influenza activity level 
were minimal and the existing microbiological surveil-
lance was able to identify the trend, start, peak and 
end of the influenza epidemics in the 2017/18 and 
2018/19 seasons. mPOCT accounted for ca 18% of all 
tests undertaken in area F, and up to 48% of all influ-
enza positive results. The increased use of mPOCT and 
increased number of positive results reinforces the 
need for accurate data capture at national level. Work is 
ongoing and HPS along with the Scottish Microbiology 
and Virology Network (SMVN) are working with labo-
ratories to standardise and improve data collection. 
However, the decision on which mPCOT machine to 
choose, and how to transfer the data is both laboratory 
and resource dependent.
It is important to note that, in addition to the micro-
biological surveillance, the national influenza surveil-
lance is composed of other components such as calls 
concerning respiratory problems to the National Health 
Service (NHS) 24 helpline, GP consultation rates for 
influenza-like illness, outbreaks, severe acute res-
piratory illness and mortality surveillance. These are 
essential not only to capture the influenza burden in 
different parts of the population/healthcare but also 
to complement each other when there are changes in 
the surveillance system, such as the introduction of 
mPOCT.
The data presented here are the first that we are aware 
of that attempt to quantify the impact that mPOCT for 
influenza has had on the information being received by 
public health authorities. We have shown the impor-
tance of recognising what mPOCT results should be 
recorded. All users need to be aware of the impact 
that each of the variables will have on the estimation 
of proportion of positives, and how the data are used 
to assess influenza activity both at local and national 
level. The main challenge is capturing the mPOCT neg-
ative results within ECOSS in order to have an accurate 
denominator and to avoid overestimating the propor-
tion of positives indicator. With this evidence now 
available, it is hoped that many of these issues can be 
addressed for future influenza seasons. While report-
ing from a Scottish perspective we anticipate that our 
observations are likely to reflect common issues found 
in other European countries in which the introduc-
tion of mPOCT for influenza pose a challenge for data 
recording, and as a consequence, the accuracy and 
completeness of surveillance information.
Limitations
There are a number of caveats to our data and it is 
important to highlight them as a way of suggesting 
areas for consideration and improvement when plan-
ning implementation of mPOCT. This study covered 
only a sample of areas in Scotland therefore the total 
impact of incomplete or lack of mPOCT data in the 
national surveillance system (ECOSS) is still unknown. 
The impact is likely to be larger if the use of mPOCT 
increases dramatically and accounts for the majority of 
influenza tests. It is also important to stress that front-
line users, e.g. nursing staff, may not always recognise 
the critical nature of recording and reporting every 
mPOCT result. Further work is required to quantify this 
and to identify laboratory-specific challenges that will 
need to be addressed. While ECOSS enhanced data 
were calculated to avoid double counting any mPOCT 
results, there may still be some instances of duplica-
tion in which identifiers were close, but not exactly 
matching. It was noted that during the 2017/18 season, 
adherence to local protocols was not always evident 
and some testing was performed on asymptomatic 
individuals, contacts or members of staff, although this 
number was minimal. There were a number of areas 
that were subject to manual data entry, which carries 
a risk of transcription errors. In order to minimise this 
risk, we recommend that all steps are automated and 
linked to the LIMS and ECOSS. The method of identify-
ing an mPOCT via text searches in ECOSS is suboptimal 
and there is the potential for misclassification. The use 
of MEM applied to microbiological surveillance data 
depends on historical data as described elsewhere 
[17]. The lack of reliable and complete microbiological 
data (including mPOCT) can therefore limit the poten-
tial application of this methodology to assess influ-
enza activity at local level where data might be limited.
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In order to address some of the issues that have been 
discussed, a separate programme to improve all micro-
biology data received at HPS is currently underway. The 
ECOSS Data Roll Out Improvement Project (EDRIP) will 
review all data received from all NHS clinical microbi-
ology laboratories in Scotland, including mPOCT data, 
over a two-year period. It is hoped that any issues 
identified will be addressed quickly to result in a con-
tinuous improvement to the quality of all data held 
within ECOSS. This will ensure that the impact of the 
influenza mPOCT programme in Scotland can be reli-
ably assessed, and effectiveness of any interventions 
monitored.
Conclusion
Through close liaison with the Scottish territorial health 
boards and respective laboratories, we have shown 
there was an improvement in mPOCT data collection 
between the 2017/18 and 2018/19 influenza seasons. 
Further work is needed to ensure accurate numbers of 
positive and negative mPOCT results are collected in 
ECOSS, including set up of direct LIMS connectivity, 
education of frontline users on the impact of missing 
results, and continued development and audit of local 
protocols. Due to the benefits for patient management, 
the use of mPOCT for influenza is likely to continue and 
implementation of these systems should be carefully 
managed in order to reduce the impact on national 
microbiological surveillance.
empirical study and modelling is required to optimise 
their use for public health benefit.
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